DBV Technologies S.A. ADR (DBVT)
NASDAQ: DBVTHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
DBVT stock chart
Technical analysisKey statistics
All statistics- Market cap
- $566.82M
- EPS (TTM)
- -$3.00
- Dividend yield
- None
- 52-week range
- 8.63 – 26.19
- Day range
- 9.00 – 9.47
- Volume / Avg
- 156.50K / 352.88K
- Beta
- —
- Shares outstanding
- 62.84M
52-week range
DBVT stock today
On Nov 20, DBVT ended the session at $9.02, shedding $0.40 (4.25%), versus the S&P 500's 3.70% decline. Trading was light, with 156.50K shares changing hands, about 44% of the average daily volume. At this level, DBVT sits near the bottom of its 52-week range of $8.63 to $26.19: 65.6% below the high, set on Dec 17, 2025 and 4.5% above the low.
DBVT is down 52.9% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 34.4%. DBV Technologies S.A. has posted a net loss over the last twelve months (EPS of -$3.00), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About DBV Technologies S.A.
Company profileDBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs include celiac disease.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Mr. Daniel Tassé
- Headquarters
- Châtillon
- Employees
- 179
- IPO year
- 2014
- Website
- dbv-technologies.com
Financial highlights
Full financialsIn fiscal 2025, DBV Technologies S.A. generated $5.6 million in revenue, up 35.8% from fiscal 2024. DBV Technologies S.A. reported a net loss of $146.9 million, compared with a loss of $113.9 million a year earlier. Operating margin was -2609.2%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $5.64M | $4.15M | $15.73M | $4.84M | $5.71M |
| Growth | +35.77% | -73.61% | +224.69% | -15.14% | -49.38% |
| Net income | $-146.95M | $-113.92M | $72.71M | $96.27M | $-97.81M |
| EPS (diluted) | $-1.05 | $-1.17 | $-0.76 | $-1.24 | $-1.78 |
Analyst forecast
ForecastConsensus (7 analysts)
buy
Avg. price target
$36.54+305.10%
- Strong buy 1
- Buy 5
- Hold 0
- Sell 1
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Oct 28, 2026
- EPS actual vs est.
- $-0.70 vs $-0.60
- Surprise
- -16.67%
DBVT news
All DBVT news- DBV Technologies présente de nouvelles données issues de l’étude de phase 3 VITESSE sur le patch VIASKIN® Peanut chez les enfants âgés de 4 à 7 ansGlobeNewswire
- DBV Technologies Highlights New Data from the VITESSE Phase 3 Study of the VIASKIN® Peanut Patch in Children Ages 4-7 YearsGlobeNewswire
- DBV Technologies to Participate in Upcoming November Investor ConferencesGlobeNewswire
- DBV Technologies participera aux prochaines Conférences Investisseurs en novembreGlobeNewswire
- DBV Technologies S.A. Reports Third Quarter 2026 Financial ResultsNasdaq
- DBV Technologies (DBVT) Q3 2026 Earnings Call TranscriptNasdaq
- DBV Technologies publie ses résultats financiers du troisième trimestre 2026 et fait le point sur ses activitésGlobeNewswire
- DBV Technologies Reports Third Quarter 2026 Financial Results and Business UpdateGlobeNewswire
DBV Technologies S.A. peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ENTXEntera Bio Ltd. | 3.31 | +0.76% | $575.53M | vs DBVT |
| FDMT4D Molecular Therapeutics Inc. | 10.23 | -4.57% | $576.76M | vs DBVT |
| CGEMCullinan Therapeutics Inc. | 8.89 | -1.98% | $577.15M | vs DBVT |
| SRZNSurrozen Inc. | 28.46 | -7.21% | $596.40M | vs DBVT |
| IAMIambic Therapeutics Inc. | 13.11 | -8.06% | $621.42M | vs DBVT |
| ETRAElectra Therapeutics Inc. | 8.11 | -9.28% | $509.85M | vs DBVT |
| VALNValneva SE ADR | 5.16 | -3.82% | $490.86M | vs DBVT |
| DNAGinkgo Bioworks Holdings Inc. Class A | 7.46 | -9.02% | $483.54M | vs DBVT |
Indexes, lists and sector
DBV Technologies S.A. stock FAQ
What is DBV Technologies S.A.'s stock price today?
DBVT last traded at $9.02 as of Nov 20, 4:00 PM EST, down 4.25% on the day. Prices are delayed at least 15 minutes.
Does DBV Technologies S.A. pay a dividend?
No. DBV Technologies S.A. does not currently pay a regular cash dividend.
Who is DBV Technologies S.A.'s CEO?
Mr. Daniel Tassé is the chief executive officer of DBV Technologies S.A. ADR, which has about 179 employees.
Has DBVT ever split its stock?
Yes. The most recent DBVT stock split was a 1-for-2 split on Jun 7, 2024.
What is the DBVT 52-week high?
The 52-week high for DBVT is $26.19 and the 52-week low is $8.63. The stock is currently 65.6% below its high.